LarnkjaerABruunSPedersenDZachariassenGBarkholtVAgostoniCet al
The results were striking: women taking GLP-1s showed a 72% improvement in natural pregnancy rates (RR: 1.72, 95% CI 1.22-2.43), meaning they were 1.72 times more likely to conceive naturally compared to the control group
The partial rescue of the above-described symptomatology can be ascribed to the activity of other transporters such as ATB 0,+ (SLC6A14), MCT9, and probably, OCTN1 (SLC22A4) that accept carnitine with a much lower affinity if compared to OCTN2
Acknowledgements We would like to thank the volunteers (and their families) whose participation made this study possible
Currently, there is no official FDA indication for GLP-1 receptor agonists specifically targeting inflammation, and clinical guidelines do not recommend this approach outside established indications
The retatrutide availability guide stays updated on supply changes and market developments